NAVAMEDIC (NAVA.OL) Stock Fundamental Analysis
OSL:NAVA - NO0010205966 - Common Stock
21.6 NOK
+0.2 (+0.93%)
NAVA gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 50 industry peers in the Pharmaceuticals industry. NAVA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. NAVA is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year NAVA has reported negative net income.
NAVA had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: NAVA reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: NAVA reported negative operating cash flow in multiple years.
1.2 Ratios
With a Return On Assets value of -1.17%, NAVA is not doing good in the industry: 66.00% of the companies in the same industry are doing better.
With a Return On Equity value of -2.53%, NAVA is not doing good in the industry: 66.00% of the companies in the same industry are doing better.
NAVA's Return On Invested Capital of 9.30% is in line compared to the rest of the industry. NAVA outperforms 58.00% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for NAVA is below the industry average of 14.78%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.17% | ||
| ROE | -2.53% | ||
| ROIC | 9.3% |
ROA(3y)1.27%
ROA(5y)-0.47%
ROE(3y)1.61%
ROE(5y)-1.5%
ROIC(3y)10.14%
ROIC(5y)N/A
1.3 Margins
With a Operating Margin value of 7.42%, NAVA perfoms like the industry average, outperforming 42.00% of the companies in the same industry.
NAVA's Operating Margin has improved in the last couple of years.
With a Gross Margin value of 39.30%, NAVA is not doing good in the industry: 76.00% of the companies in the same industry are doing better.
NAVA's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.42% | ||
| PM (TTM) | N/A | ||
| GM | 39.3% |
OM growth 3Y13.14%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.68%
GM growth 5Y5.2%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so NAVA is still creating some value.
Compared to 1 year ago, NAVA has more shares outstanding
Compared to 5 years ago, NAVA has more shares outstanding
NAVA has a better debt/assets ratio than last year.
2.2 Solvency
NAVA has an Altman-Z score of 2.81. This is not the best score and indicates that NAVA is in the grey zone with still only limited risk for bankruptcy at the moment.
NAVA has a Altman-Z score (2.81) which is in line with its industry peers.
NAVA has a debt to FCF ratio of 3.29. This is a good value and a sign of high solvency as NAVA would need 3.29 years to pay back of all of its debts.
NAVA has a better Debt to FCF ratio (3.29) than 64.00% of its industry peers.
A Debt/Equity ratio of 0.37 indicates that NAVA is not too dependend on debt financing.
NAVA has a Debt to Equity ratio of 0.37. This is comparable to the rest of the industry: NAVA outperforms 60.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.37 | ||
| Debt/FCF | 3.29 | ||
| Altman-Z | 2.81 |
ROIC/WACC1.21
WACC7.66%
2.3 Liquidity
A Current Ratio of 1.42 indicates that NAVA should not have too much problems paying its short term obligations.
NAVA has a Current ratio (1.42) which is comparable to the rest of the industry.
NAVA has a Quick Ratio of 1.42. This is a bad value and indicates that NAVA is not financially healthy enough and could expect problems in meeting its short term obligations.
NAVA has a Quick ratio (0.84) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.42 | ||
| Quick Ratio | 0.84 |
3. Growth
3.1 Past
NAVA shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -5.58%.
NAVA shows a small growth in Revenue. In the last year, the Revenue has grown by 6.15%.
NAVA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 23.00% yearly.
EPS 1Y (TTM)-5.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-364.67%
Revenue 1Y (TTM)6.15%
Revenue growth 3Y24.05%
Revenue growth 5Y23%
Sales Q2Q%9.23%
3.2 Future
NAVA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 31.39% yearly.
NAVA is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 13.03% yearly.
EPS Next Y-81.87%
EPS Next 2Y2.39%
EPS Next 3Y18.86%
EPS Next 5Y31.39%
Revenue Next Year12.65%
Revenue Next 2Y18.54%
Revenue Next 3Y16.76%
Revenue Next 5Y13.03%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
NAVA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 15.92 indicates a correct valuation of NAVA.
The rest of the industry has a similar Price/Forward Earnings ratio as NAVA.
NAVA's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 22.69.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 15.92 |
4.2 Price Multiples
86.00% of the companies in the same industry are more expensive than NAVA, based on the Enterprise Value to EBITDA ratio.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of NAVA indicates a somewhat cheap valuation: NAVA is cheaper than 78.00% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.21 | ||
| EV/EBITDA | 7.03 |
4.3 Compensation for Growth
NAVA's earnings are expected to grow with 18.86% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.39%
EPS Next 3Y18.86%
5. Dividend
5.1 Amount
No dividends for NAVA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
OSL:NAVA (9/5/2025, 7:00:00 PM)
21.6
+0.2 (+0.93%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners32.09%
Inst Owner ChangeN/A
Ins Owners16.59%
Ins Owner ChangeN/A
Market Cap512.14M
Analysts82.86
Price Target40.8 (88.89%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-9.93%
Min Revenue beat(2)-17.93%
Max Revenue beat(2)-1.92%
Revenue beat(4)1
Avg Revenue beat(4)-6.45%
Min Revenue beat(4)-17.93%
Max Revenue beat(4)3.23%
Revenue beat(8)3
Avg Revenue beat(8)-0.95%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)12.99%
PT rev (3m)25%
EPS NQ rev (1m)-1.66%
EPS NQ rev (3m)-1.66%
EPS NY rev (1m)-68.28%
EPS NY rev (3m)-68.28%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)3.53%
Revenue NY rev (3m)2.42%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 15.92 | ||
| P/S | 0.96 | ||
| P/FCF | 14.21 | ||
| P/OCF | 13.01 | ||
| P/B | 2.36 | ||
| P/tB | N/A | ||
| EV/EBITDA | 7.03 |
EPS(TTM)-0.71
EYN/A
EPS(NY)1.36
Fwd EY6.28%
FCF(TTM)1.52
FCFY7.03%
OCF(TTM)1.66
OCFY7.68%
SpS22.41
BVpS9.14
TBVpS-1.47
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.17% | ||
| ROE | -2.53% | ||
| ROCE | 12.08% | ||
| ROIC | 9.3% | ||
| ROICexc | 11.12% | ||
| ROICexgc | 140.87% | ||
| OM | 7.42% | ||
| PM (TTM) | N/A | ||
| GM | 39.3% | ||
| FCFM | 6.78% |
ROA(3y)1.27%
ROA(5y)-0.47%
ROE(3y)1.61%
ROE(5y)-1.5%
ROIC(3y)10.14%
ROIC(5y)N/A
ROICexc(3y)12.6%
ROICexc(5y)N/A
ROICexgc(3y)98.8%
ROICexgc(5y)N/A
ROCE(3y)13.17%
ROCE(5y)N/A
ROICexcg growth 3Y90.11%
ROICexcg growth 5YN/A
ROICexc growth 3Y12.82%
ROICexc growth 5YN/A
OM growth 3Y13.14%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.68%
GM growth 5Y5.2%
F-Score6
Asset Turnover1.14
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.37 | ||
| Debt/FCF | 3.29 | ||
| Debt/EBITDA | 1.01 | ||
| Cap/Depr | 8.24% | ||
| Cap/Sales | 0.63% | ||
| Interest Coverage | 5.07 | ||
| Cash Conversion | 49.31% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.42 | ||
| Quick Ratio | 0.84 | ||
| Altman-Z | 2.81 |
F-Score6
WACC7.66%
ROIC/WACC1.21
Cap/Depr(3y)19.25%
Cap/Depr(5y)40.99%
Cap/Sales(3y)0.55%
Cap/Sales(5y)0.86%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-5.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-364.67%
EPS Next Y-81.87%
EPS Next 2Y2.39%
EPS Next 3Y18.86%
EPS Next 5Y31.39%
Revenue 1Y (TTM)6.15%
Revenue growth 3Y24.05%
Revenue growth 5Y23%
Sales Q2Q%9.23%
Revenue Next Year12.65%
Revenue Next 2Y18.54%
Revenue Next 3Y16.76%
Revenue Next 5Y13.03%
EBIT growth 1Y67.35%
EBIT growth 3Y40.35%
EBIT growth 5YN/A
EBIT Next Year22.79%
EBIT Next 3Y27.28%
EBIT Next 5Y26.96%
FCF growth 1Y189721%
FCF growth 3YN/A
FCF growth 5Y24.61%
OCF growth 1Y1706.01%
OCF growth 3YN/A
OCF growth 5Y25.36%